Thomasville National Bank Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Thomasville National Bank boosted its stake in Pfizer Inc. (NYSE:PFE) by 1.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 90,710 shares of the biopharmaceutical company’s stock after acquiring an additional 1,449 shares during the period. Thomasville National Bank’s holdings in Pfizer were worth $2,625,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. V Square Quantitative Management LLC grew its position in Pfizer by 260.1% during the fourth quarter. V Square Quantitative Management LLC now owns 20,985 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 15,158 shares during the period. Sierra Summit Advisors LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $209,000. Scarborough Advisors LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $124,000. Creekmur Asset Management LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $32,000. Finally, Twin Focus Capital Partners LLC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $344,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

PFE has been the topic of several recent analyst reports. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Barclays raised their target price on shares of Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Daiwa Capital Markets raised shares of Pfizer from a “neutral” rating to an “outperform” rating and upped their price target for the stock from $28.00 to $34.00 in a research report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Stock Down 0.6 %

Shares of Pfizer stock opened at $29.16 on Monday. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a 50-day moving average price of $29.04 and a 200 day moving average price of $28.39. Pfizer Inc. has a fifty-two week low of $25.20 and a fifty-two week high of $33.92. The firm has a market cap of $165.24 billion, a P/E ratio of -486.00, a P/E/G ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.14. The company had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.67 earnings per share. On average, sell-side analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a dividend yield of 5.76%. Pfizer’s dividend payout ratio is presently -2,800.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.